ABSTRACT
Objective To observe the lung protection of Astragalus membranaceus against radiotherapy to intermediate-stage and terminal thoracic neoplasm, and its influence on TNF-α and ET expression.Methods The patients with intermediate-stage and terminal thoracic neoplasm under radiotherapy were divided into a treatment group and a control group.Patients in the treatment group took 10 ml of Asragalus membranaceus twice a day.for consecutive 6 months from the beginning of radio therapy.TNF-α and ET in the plasma were measured before and after the radiotherapy.The clinical symptom,iconographic changes and lung diffusion were observed from the 15th day of radiotherapy.Results The TNF-α and ET in plasma afterthe radiotherapy were(2.48±0.75)as/ml and(69.32±23.03)pg/ml for the treatment group,and(5.12±1.01)ns/ml and(97.87±37.83)pg/ml for the control group with the statistial difference(x2=7.49,6.57,P<0.001).The decrease of CO diffusion 5 and 10 months after the radiotherapy in the treatment group was statistically different compared with that in the control group(x2=3.98,3.78,P<0.05).There was a statistical difference of the incidence of acute radiation pneumonitis and pulmonary fibrosis between these two groups(P<0.05).Conclusions Astragalus membranaceus could inhibit the excess expression of TNF-α and ET in plasma and reduce the deterioration of diffusion after radiotherapy,so that it can be used for intervention of lung injuries from radiotherapy.
ABSTRACT
OBJECTIVE:To observe the effect of Qinzao jiufei decoction on radiation-induced lung injury and expression of plasma transforming growth factor beta-1(TGF-?1)and interleukin-1(IL-1).METHODS:Local middle and advanced thoracic tumor patients with radiotherapy were randomized into treatment group and control group. Both groups were given radiotherapy. Treatment group were additionally given Qingzao jiufei decoction (200 mL,b.i.d.) for 6 months. The level of TGF-?1 and IL-1 were determined before and after radiotherapy. After 15 days of radiotherapy,clinical symptoms,lung function and high-resolution CT manifestation of thorax were evaluated. RESULTS:There were statistical significance between two groups in respect of TGF-?1 and IL-1 in serum(P
ABSTRACT
OBJECTIVE:To observe the therapeutic effect of Shenfu Injection in combination of rougui for oxaliplatin-induced neurotoxicity.METHODS:A total of 73 cases with malignant tumor were randomly divided into control group and treatment group:the control group was treated with chemotherapy alone,in which oxaliplatin was included;the treatment group was treated intravenously with Shenfu Injection 40～60ml for 7～10d plus orally with 3g Rougui decoction prior to chemothera_py.RESULTS:Incidences of neurotoxicity for the treatment group and the control group were 13.5% and 55.6%,respectively.Significant differences were noted between 2 groups(P
ABSTRACT
800 ng/L) and elevated NO content were enrolled to study the efficacy of treatment with a combination of drugs for heat- reducing, purgation, resolving and tonification for 6 months to 2 years. The symptoms and signs were markedly ameliorated: the level of GPT, GOT, globulin, albumin and bilirubin contents restored to normal level. In B -ultrasonographic examination, a decrease the width of the portal vein and the spleen was found in 50% of the patients. The authors concluded that the combined use of drugs for heat- reducing, purgation, resolving and tonification was effective in treating hyperhyaluronemia due to liver cirrhosis. The ingredient rhemannia root may play the key role in its actions of expelling toxic materials, normalizing the functions of the viscera and discharge of bile, and removing the stagnated heat.